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ABSTRACT
The bone morphogenetic protein (BMP) and Wnt signaling pathways both contribute essential roles in regulating bone mass. However,
the molecular interactions between these pathways in osteoblasts are poorly understood. We recently reported that osteoblast-targeted
conditional knockout (cKO) of BMP receptor type IA (BMPRIA) resulted in increased bone mass during embryonic development, where
diminished expression of Sost as a downstream effector of BMPRIA resulted in increased Wnt/b-catenin signaling. Here, we report that
Bmpr1a cKO mice exhibit increased bone mass during weanling stages, again with evidence of enhanced Wnt/b-catenin signaling as
assessed by Wnt reporter TOPGAL mice and TOPFLASH luciferase. Consistent with negative regulation of the Wnt pathway by BMPRIA
signaling, treatment of osteoblasts with dorsomorphin, an inhibitor of Smad-dependent BMP signaling, enhanced Wnt signaling. In
addition to Sost, Wnt inhibitor Dkk1 also was downregulated in cKO bone. Expression levels of Dkk1and Sost were upregulated by BMP2
treatment and downregulated by Noggin. Moreover, expression of a constitutively active Bmpr1a transgene in mice resulted in the
upregulationofbothDkk1andSostandpartiallyrescuedtheBmpr1acKObonephenotype.Theseeffectorsaredifferentiallyregulatedby
mitogen-activated protein kinase (MAPK) p38 because pretreatment of osteoblasts with SB202190 blocked BMP2-induced Dkk1
expression but not Sost. These results demonstrate that BMPRIA in osteoblasts negatively regulates endogenous bone mass and Wnt/b-
catenin signaling and that this regulation may be mediated by the activities of Sost and Dkk1. This study highlights several interactions
between BMP and Wnt signaling cascades in osteoblasts that may be amenable to therapeutic intervention for the modification of bone
mass density.  2010 American Society for Bone and Mineral Research.
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Introduction
B
one morphogenetic proteins (BMPs), originally discovered as
inducersofectopicbone,
(3)aremembersofthetransforming
growthfactorb(TGF-b)superfamily.
(1,2)BMPsignals,likethoseof
other TGF-b family members, are mediated by the concerted
activation of type I and type II serine-threonine kinase
receptors.
(4)OnengagingBMPligandsinaheteromeric complex,
type II receptors activate the kinase function of type I receptors
to initiate signaling via intracellular Smads 1, 5, and 8. Of the
three type I receptors that recognize BMPs (BMPRIA or ALK3,
BMPRIB or ALK6, and ACVRI or ALK2), BMPRIA is the most
effective receptor for transducing canonical BMP ligands BMP2
(5)
and BMP4,
(6) which are abundantly expressed in bone.
(7)
The osteogenic function of BMPs has been documented
extensively, with numerous in vitro studies supporting a critical
role of BMP signaling in osteoblastogenesis.
(8) While constitutive
activation of BMP signaling in muscle appears to induce ectopic
ossification in patients with fibrodysplasia ossificans progres-
siva
(9) and in a mouse model,
(10) the physiologic effects of BMP
signaling on endogenous bone formation in vivo have not been
fully elucidated. The early embryonic lethality of conventional
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200knockout mice deficient in BMP ligands and receptors prior to
bone development has precluded these studies.
(11–13) To
circumvent this lethality, we recently generated conditional
knockout (cKO) mice in which BMP signaling through BMPRIA
was disrupted in a bone-specific and age-dependent manner
usingatamoxifen-inducibleCre/loxPsystemunderthecontrolof
a 3.2kb type I collagen promoter. In these Bmpr1a cKO mice,
we unexpectedly observed increased bone mass in embryos,
weanlings, and adult animals.
(14,15) In cKO adult bones, increased
bone mass resulted from severely suppressed bone resorption
owing to reduced RANKL-OPG pathway-induced osteoclasto-
genesis despite a simultaneous small reduction in the rate of
bone formation.
(15) These findings suggest that BMP signaling in
osteoblasts regulates the balance between bone formation and
resorption to control bone mass.
Wnt signaling in osteoblasts also plays an important role in
regulating bone formation and mass.
(16–20) Experiments using
pluripotent mesenchymal cell lines to test the interaction
between BMP and Wnt signaling in osteoblasts have yielded
somewhat contradictory results. BMP2 has been reported to
induce both Wnt3a and Wnt/b-catenin signaling,
(21–23) whereas
Wnt3a, in turn, enhances BMP4 expression.
(24) However, Wnt3a
also has been reported to repress BMP2-dependent Id1
expression.
(25) In contrast, we recently demonstrated that loss
ofBMPRIAsignalinginosteoblastsdownregulatessclerostin/Sost
and upregulates Wnt/b-catenin signaling, resulting in increased
bone mass during embryonic stages.
(14) Our results provide a
potential mechanism by which BMP signaling in osteoblasts
negatively regulates Wnt signaling to control fetal bone mass.
Since BMPs are used clinically to improve fracture healing,
(26)
our previous findings of increased bone mass in Bmpr1a-
deficient mice is unexpected and contrary to the rationale
behind the application of BMPs in orthopedics. This study seeks
to elucidate further the molecular mechanism by which BMP
signaling regulates bone mass. Here we report that loss of
BMPRIA in postnatal osteoblasts increases bone mass via
upregulation of Wnt/b-catenin signaling. In addition to Sost,
we find that Wnt inhibitor Dkk1 is also a downstream target of
BMPRIA signaling in osteoblasts, lending further support for a
negative regulation of Wnt signaling via BMPRIA.
Materials and Methods
Mice and tamoxifen administration
A transgenic mouse line expressing the tamoxifen (TM)–
inducible Cre fusion protein Cre-ER
TM under the control of a
3.2kb mouse procollagen a1(I) promoter (Col1-CreER
TM) was
generated by pronuclear injection
(14,15) and crossed with floxed
Bmpr1a mice.
(27) TM (T5648, Sigma, St. Louis, MO, USA) was
dissolved in a small volume of ethanol, diluted with corn oil at a
concentration of 10mg/mL, and stored at  208C until use. To
generate Bmpr1a cKO mice (Col1-CreER
TMþ:Bmpr1a
fx/fx) and
littermate controls (Col1-CreER
TM–:Bmpr1a
fx/fx) in weanling
stages, TM (75mg/kg) was injected intraperitoneally (i.p.) into
nursing females every 3 days from P2 until euthanasia at P10,P 14,
or P21.
(15) Mice that conditionally express a constitutively active
form of Bmpr1a (caBmpr1a), which has a mutation in the glycine
and serine residue (GS) regulatory domain of BMPRIA (Q227D)
resulting in ligand-independent activation of Smad signaling
after Cre recombination, were generated as reported pre-
viously
(14) and crossed with Col1-CreER
TM mice. After injection of
TM into nursing females every 3 days from P2 to P21,c a Bmpr1a
mutant mice (Col1-CreER
TMþ:caBmpr1a
þ) were compared with
littermate controls (Col1-CreER
TM–:caBmpr1a
þ). Both received TM
through milk until sacrifice. ROSA26 Cre reporter (R26R)
(28) and
TOPGAL
(29)micewereobtainedfromDr.PhilippeSorianoandthe
Jackson Laboratory, respectively. C57BL/6 and CD1 mice were
used for isolation of wild-type osteoblasts and calvaria culture.
The animal protocol was approved by the Institutional Animal
Care and Use Committee (IACUC) at the NIEHS/NIH.
Histology
For hematoxylin and eosin (H&E) staining, rib cages and skulls
were fixed in 4% paraformaldehyde, decalcified with 10% EDTA,
and embedded in paraffin. Paraffin sections were cut at 8mm
and stained using a standard protocol. For b-galactosidase
(b-gal) staining, decalcified bones were prepared in 30% sucrose
before frozen sectioning. Sections were stained with X-gal for
b-gal activity and counterstained with eosin. Whole rib bones
and skulls also were stained with X-gal as previously.
(14,15) For
immunofluorescence, osteoblasts from newborn cKO and
littermate controls were fixed with 4% paraformaldehyde for
10 minutes, and immunostaining was performed using rabbit
polyclonal antibodies against b-gal (1:100, Cappel Laboratories,
Inc., Cochranville, PA, USA) and antirabbit IgG labeled with Alexa
Fluor 488 (1:1000, Invitrogen, Carlsbad, CA, USA). Nuclei were
stained with 4,6-diamidino-2-phenylindole (DAPI) (10mg/mL,
Sigma) for 10 minutes. Then b-gal-positive cells per DAPI-
positive cells were calculated (%) in the same field.
X-ray and DXA analyses
X-ray images of rib cages from P21 mice were taken using a
Faxitron X-raysystem(Faxitron X-Ray,Lincolnshire,IL,USA).Bone
mineral density (BMD) was determined by dual-energy X-ray
absorptiometry (DXA) using the Lunar PIXImus2 densitometer
(GE, Fairfield, CT, USA).
Quantitative real-time RT-PCR (qRT-PCR)
RNA was isolated from P21 rib bones using Trizol (Invitrogen) and
from primary osteoblasts using Picopure (Arcturus, Sunnyvale,
CA, USA). cDNA was synthesized using the SuperScript
Preamplification System (Invitrogen). PCR reactions, data
quantification, and analysis were performed according to the
manufacturer’s standard protocol of TaqMan gene expression
assays: Axin2: Mm01265783_m1, Bmpr1a: Mm00477650_m1,
Ctgf: Mm01192931_g1, Dkk1: Mm00438422_m1, Lef1:
Mm00550265_m1, Lrp5: Mm01227476_m1, and Sost:
Mm03024247_g1 (Applied Biosystems, Rotkreuz, Switzerland).
Values were normalized to Gapdh using TaqMan Rodent GAPDH
Control Reagents (Applied Biosystems). All measurements were
performed in triplicate and analyzed using the 2
 DDC(t
method.
(30)
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NewbornandP10calvariae weredigested withtypeIcollagenase
(Sigma) and dispase II (Roche, Indianapolis, IN, USA) to isolate
osteoblasts, as described previously.
(14) Primary osteoblasts were
maintained in a-MEM containing 10% fetal bovine serum (FBS)
and ascorbic acid (50mg/mL, Sigma). Primary osteoblasts from
wild-type mice were treated with BMP2 for 3 hours at varied
concentrations (10, 50, and 100ng/mL, R&D, Minneapolis, MN,
USA). Wild-type osteoblasts also were pretreated with dorso-
morphin (10mM), p38 mitogen-activated protein kinase (MAPK)
inhibitor SB202190 (10mM, Calbiochem, Gibbstown, NJ, USA),
and DMSO in the absence of serum for 1 hour before BMP2
treatment (100ng/mL). For primary osteoblasts from Bmpr1a
cKO mice or caBmpr1a mutant mice, 4-hydroxyl tamoxifen (4OH
TM, 100ng/mL, Sigma) was added in culture every other day. For
ex vivo bone culture, newborn calvariae from wild-type mice
were dissected at the sagittal suture and cultured in modified
BGJ (Invitrogen) supplemented with 5% FBS and ascorbic acid
(50mg/mL) for the first 24 hours in culture. Hemicalvariae were
treated with 4OH TM (100ng/mL) and Noggin (100ng/mL, R&D)
in the absence of serum for 5 days.
Dual luciferase reporter assays
Primary osteoblasts from Bmpr1a cKO newborn mice and their
littermatecontrolswereplatedontosix-wellplatesatadensityof
2 10
5cells/well containing 10% FBS in a-MEM and grown to
50% to 60% confluence. Cells were transfected with plasmid
mixtures containing 2mg TOPFLASH luciferase construct and
0.05mg Renilla luciferase driven by the Drosophila actin 5C
promoter
(31) (kindly provided by Dr. Paul A. Wade) using FuGENE
6 Transfection Reagent (Roche) according to the manufacturer’s
protocol. After 48 hours of transfection, the cells were lysed, and
luciferase activity was measured. The values of TOPFLASH
luciferase activity were normalized to those of Renilla activity
using a dual luciferase assay kit (Promega, Madison, WI, USA). For
dorsomorphin treatment, primary osteoblasts from wild-type
mice were transfected as described, cultured for 40 hours,
treated with DMSO or dorsomorphin (10mM) and further
incubated for 8 hours. The dual luciferase assay was performed
in the same manner as described previously. No obvious toxicity
was detected in the experiments based on Renilla levels.
Statistical analysis
All statistical analyses were performed using a two-tailed
Student’s t test.
Results
Tissue specificity and efficiency of Cre recombinase in
Col1-CreER
TM mice
TM-inducible Col1-CreER
TM mice were mated to ROSA26 reporter
mice (R26R) to assess Cre activity by staining for b-galactosidase
(b-gal) at P21. TM was injected intraperitoneally into nursing
females every 3 days from P2 to P20. Cre transgenic mice
administered TM (Col1-CreER
TMþ, ROSA
þ,T M
þ) stained for b-gal
in rib bones (Fig. 1A, a), where many osteoblasts and osteocytes
showed evidence of recombination (see Fig. 1A, b). No staining
was observed in cartilage (see Fig. 1A, a). At this stage, no
recombination was detected in chondrocytes and osteoclasts, as
described previously.
(15) These results demonstrate that the TM
administration delivered through milk specifically and efficiently
induces Cre recombination in osteoblasts and osteocytes in
weanlings.
Fig. 1. Increased bone mass in Bmpr1a cKO weanling mice. Tamoxifen
was injected intraperitoneally into nursing females every 3 days from P2
to P20.( A) ROSA26 Cre reporter mice showed Cre activity on rib bones
stained with b-galactosidase (b-gal) at P21 (a). Cre-dependent DNA
recombination was detected in osteoblasts in rib bones by b-gal staining
(b). The asterisk indicates negative staining for b-gal on rib cartilage. Bar:
100mm. (B) Radiodensity of rib bones and sternum was increased in cKO
mice (Cre
þ, Bmpr1a
fx/fx) compared with controls (Cre
–, Bmpr1a
fx/fx) when
assessed by X-ray imaging at P21. Rib flaring in cKO mice is shown (right
panel). (C) BMD was determined in ribs using DXA at P21. Values are
expressed as mean SD (control: n¼10; cKO: n¼12). The asterisk
indicates a statistically significant difference between control and cKO
(mean SD; t test;
 p<.04). (D) H&E staining of P21 rib bones. Rib bones
were thicker in cKO mice, and bone mass was increased compared
with littermate controls in both the diaphysis (upper panels) and meta-
physis (lower panels). Bars: 1mm (upper panels), 500mm( lower panels).
(E) qRT-PCR analysis for Bmpr1a using P21 rib bones (mean SD; t test;
  p<.02).
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Col1-CreER
TM mice were bred with mice homozygous for floxed
Bmpr1atogenerateBmpr1acKOmice(cKO,Cre
þ:Bmpr1a
fx/fx)and
wild-type controls (Cre
–:Bmpr1a
fx/fx) after maternal TM admin-
istration. X-ray analysis demonstrated a modest increase
in radiodensity in the rib bones and sternum (see
Fig. 1B, upper panel) and rib flaring (see Fig. 1B, lower panels)
in cKO mice at P21. BMD measured by DXA was significantly
increased in rib bones at P21 (see Fig. 1C). Consistent with X-ray
imaging and DXA results, H&E staining showed that rib bones in
the diaphysis and metaphysis of cKO mice were thicker and had
higher bone mass compared with control mice at P21 (see
Fig. 1D). Bmpr1a expression was 80% reduced in cKO rib bones
at P21, as assessed by qRT-PCR (see Fig. 1E). Bone mass in other
bones (i.e., femur, tibia, humerus, tail, and calvaria) also was
increased by histology, as previously described,
(15) but BMD was
unchanged in other bones at this stage (data not shown). Thus
we focused on rib bones to investigate the mechanism by which
BMP signaling regulates bone mass.
Upregulation of canonical Wnt signaling
in cKO rib bones
Whereas BMP and Wnt signaling are known to independently
contribute to bone mass regulation,
(17–20) the interaction
between these two pathways is incompletely defined and has
not been demonstrated previously in vivo. We recently reported
that loss of BMPRIA in osteoblasts during embryogenesis
upregulates canonical Wnt signaling in mice.
(14) To assay
canonical Wnt signaling in situ, cKO mice were mated with
TOPGAL Wnt reporter mice, which express a b-galactosidase
transgene driven by a T-cell factor (TCF) b-catenin-responsive
promoter.
(29) cKO TOPGAL mice demonstrated increased Wnt
signaling activity in cKO rib bones at P14 compared with controls
when assessed by whole mount (Fig. 2A, upper panels) and
sections (see Fig. 2A, lower panels) via b-gal staining, as were
calvariae at P10 and P14 (see Fig. 2B; data not shown). Consistent
with P21 cKO calvariae,
(15) P10 cKO calvariae also were thicker
than controls (see Fig. 2B, lower panels). Upregulation of
canonical Wnt signaling in cKO rib bones and calvariae thus
was found in conjunction with increased bone mass.
Consistent with findings in cKO rib bones, canonical Wnt
signaling activity was enhanced in primary osteoblasts isolated
from P10 calvariae from cKO mice compared with control
osteoblasts (see Fig. 2B). The frequency of b-gal-positive cells
was increased significantly in cKO primary osteoblasts compared
with control osteoblasts (control: 2.8%, cKO: 20.8%; Fig. 3A).
When Lef/Tcf-dependent transcriptional activity was assayed
using the TOPFLASH reporter system, canonical Wnt signaling
was significantly increased in cKO osteoblasts (see Fig. 3B).
Corroborating the effects of targeted disruption of BMPRIA in
osteoblasts, Wnt signaling activity also was increased signifi-
cantly (see Fig. 3C) after treating wild-type primary osteoblasts
with dorsomorphin, a selective BMP type I receptor inhibitor that
effectively blocks BMPRIA-mediated Smad activation under
these conditions.
(32) Taken together, these findings in primary
osteoblasts, calavarial explants, and in situ in transgenic reporter
mice confirm that osteoblast BMPRIA signaling negatively
regulates canonical Wnt signaling during early postnatal
development and that its disruption is associated with increased
bone mass.
Downregulation of Dkk1 and Sost in cKO bones
To confirm the findings of enhanced canonical Wnt signaling in
cKO tissues and primary cultures, expression of Wnt-related
target genes was examined by qRT-PCR using rib bones and
primary osteoblasts isolated from calvariae. In P21 cKO rib bones,
expression levels of Wnt target genes Axin2, Ctgf, and Lef1 were
increased significantly (Fig. 4A). It has been reported that
osteoblasts secrete several proteins into bone extracellular
matrix (ECM) that inhibit Wnt signaling and that these ECM
molecules can regulate bone mass along with coreceptors.
(33–38)
We reported that sclerostin/Sost, a Wnt inhibitor, plays an
important role in regulating bone mass as a downstream target
Fig. 2. Upregulation of canonical Wnt signaling in Bmpr1a cKO mice. (A)
Canonical Wnt signaling in P14 rib bones assessed using TOPGAL mice.
Whole-mount b-gal staining showed increased staining in cKO rib bones
compared with controls (upper panels). Histologic analysis showed an
increased number of b-gal-positive osteoblasts in cKO rib bones com-
pared with controls (lower panels). Bar: 200mm. (B) Canonical Wnt
signaling in P10 skull bones assessed using TOPGAL mice. Whole-mount
b-galstainingshowedincreasedstainingin cKOcalvariaecomparedwith
controls (upper panels). Histologic analysis showed an increased number
of b-gal-positive osteoblasts in cKO calvariae compared with controls
(lower panels). Dotted lines indicate the sagittal suture. Bar: 100mm.
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ment.
(14) In P21 cKO rib bones, expression levels of Sost and Dkk1
mRNAswere reduced significantly, whereas levels of Wnt ligands
(Wnt3a, Wnt5a, Wnt7a, Wnt7b, and Wnt9a), other Wnt inhibitors
including Dkk2, secreted frizzled-related proteins (sFrp), and
coreceptorLrp5wereunchanged(seeFig.4B;datanotshown).In
cKO primary osteoblasts, where Bmpr1a expression was reduced
significantly, Sost and Dkk1 mRNA expression levels also were
reduced compared with controls (see Fig. 4C), whereas Wnt
target genes were increased (data not shown). Consistent with a
positive regulatory effect of BMP signaling on Wnt antagonists,
treatment of wild-type calvariae with Noggin, a BMP2 and BMP4
antagonist, inhibited both Sost and Dkk1 expression ex vivo (see
Fig. 4D), upregulated Wnt signaling,
(14) and increased the
expression of Wnt target genes (data not shown). These results
obtained from two different types of bone (i.e., rib bone and
calvaria) and primary cultures suggest that loss of BMPRIA
signaling enhances canonical Wnt signaling during postnatal
bone development in osteoblasts via decreased expression of
Dkk1 and Sost.
Positive regulation of Dkk1 and Sost by BMP2
We next investigated a potential link between expression of Wnt
inhibitors Sost and Dkk1 and BMP signaling using wild-type
primary osteoblasts. In primary osteoblasts treated with
canonical BMPRIA ligand BMP2,
(5) levels of Dkk1 and Sost
increased up to 8- and 20-fold, respectively, after 3 hours, as
assessedbyqRT-PCR(Fig.5A).PeakexpressionlevelsofDkk1and
Sost were detected at 3 hours after BMP2 treatment (100ng/mL)
(see Fig. 5B). Upregulation of Dkk1 and Sost expression by BMP2
treatment (100ng/mL) was blocked by pretreatment with
dorsomorphin (see Fig. 5C), which selectively inhibits Smad
activation without inhibiting BMP-induced activation of MAPK
p38.
(32) These results suggest that Dkk1 and Sost expression are
regulated by BMP signaling, at least in part via Smad-dependent
signaling.
Upregulation of Dkk1 and Sost by Smad-dependent
BMPRIA signaling
On ligand binding, BMPRIA phosphorylates BMP-responsive
Smads (Smad1, Smad5, and Smad8) to induce nuclear
translocation.
(39) The introduction of certain mutations in the
GS regulatory domain of BMPRIA is thought to render the
receptor protein active independent of ligand, resulting in
‘‘constitutively active’’ Bmpr1a (caBmpr1a).
(40) To confirm
whether our observations on the effects of Smad-dependent
BMPRIA signaling on Dkk1 and Sost expression were recapitu-
lated in vivo, we generated inducible transgenic mice that
conditionally express caBmpr1a, as we described previously.
(14)
These mice were crossed with Col1-CreER
TM mice, primary
osteoblasts were obtained from newborn calvariae, and then
Smad-dependent BMPRIA signaling was induced by adminis-
trationof4OHTMintotheculturemedium.BothDkk1expression
Fig. 3. Upregulation of canonical Wnt signaling by loss of BMP signaling
in vitro. (A) Detection of canonical Wnt signaling in primary osteoblasts
from P10 Bmpr1a cKO and control calvariae (upper panels) using TOPGAL
mice assessed by immunocytochemical staining for b-gal (green). Nuclei
werestainedwithDAPI(blue,lowerpanels).Relativeratioofb-gal-positive
cell number to DAPI-positive cell number was determined in the same
field (mean from 50 fields; t test;
 p<.01; n > 4 per each genotype). Bars:
200mm. (B) TOPFLASH plasmid was cotransfected with pRL-actin vector
into primary osteoblasts from newborn Bmpr1a cKO and wild-type
control calvariae using FuGENE 6 for 48 hours. Transfection efficiency
for luciferase activity was normalized to Renilla luciferase (pRL-actin
vector) activity. The y axis shows relative luciferase units (RLUs, luciferase
activity/Renilla units). Promoter activities for Lef/Tcf-dependent transcrip-
tion were increased significantly in cKO osteoblasts (mean SD; t test;
  p<.02). (C) Effects of BMP signaling inhibitor dorsomorphin on cano-
nical Wnt signaling in vitro. TOPFLASH plasmid was cotransfected with
pRL-actin vector into primary osteoblasts from newborn wild-type cal-
variae using FuGENE 6. After 40 hours of transfection, these cells were
treated with dorsomorphin (10mM) or DMSO without serum for 8 hours,
and then cells were harvested. The Lef/Tcf-dependent transcriptional
activities were increased significantly by the treatment with dorsomor-
phin, as measured by dual luciferase activity (mean SD; t test;
   p<.05).
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increased, 5- and 10-fold, respectively, in caBmpr1a osteoblasts
(Cre
þ,c a Bmpr1a
þ) compared with controls (Cre
–,c a Bmpr1a
þ)
(Fig. 6A). We next generated compound transgenic-knockout
mice expressing caBmpr1a on a Bmpr1a cKO background
(rescued: Cre
þ,c a Bmpr1a
þ, Bmpr1a
fx/fx) and compared them to
littermate Bmpr1a cKO mice (cKO: Cre
þ,c a Bmpr1a
–, Bmpr1a
fx/fx)
or controls (Cre
–,c a Bmpr1a
þ, Bmpr1a
fx/fx). X-ray imaging
demonstrated a moderate reduction in radiodensity of the rib
bones and sternum obtained from compound transgenic-
knockout mice compared with Bmpr1a cKO mice at P21 (see
Fig.6B).Inaddition,theobservationofincreasedBMDincKOribs
and sternum was abrogated by enhanced Smad-dependent
BMPRIA signaling at P21 (see Fig. 6C). These results using
induciblecompound caBmpr1atransgenicandBmpr1acKOmice
demonstrate that both Dkk1 expression and Sost expression are
positivelyregulatedbyBMPRIA-mediatedSmadsignalinginvivo,
with effects on bone mineral density that are most concordant
with effects on Wnt pathway regulation.
Effects of activation of a non-Smad pathway on
Dkk1 and Sost expression
Rib flaring was still observed in the compound transgenic
knockout mice (see Fig.6B),and the BMD ofthe rescued sternum
wassignificantlyhigherthanthatofcontrolsternum(seeFig.6C).
The partial rescue of the cKO phenotype by the constitutively
active transgene led us to postulate that loss of BMP signaling
through Smad-independent pathways in addition to the Smad-
dependentpathwaymaycontributetothecKObonephenotype.
BMP signaling can activate intracellular effectors, in particular
p38 MAPK, via Smad-dependent pathways both in vitro and in
vivo.
(41–45) To investigate whether regulation of Dkk1 and Sost
expression by BMPRIA signaling requires activation ofp38 MAPK,
we pretreated primary wild-type osteoblasts with a p38 MAPK
inhibitor SB202190 (10mM) before BMP2 treatment (100ng/mL).
Upregulation of Dkk1 expression by BMP2 treatment was
blocked by SB202190 pretreatment, as assessed by qRT-PCR
(Fig. 7A). In contrast, Sost expression was increased significantly
Fig. 4. Downregulation of Dkk1 and Sost in Bmpr1a cKO rib bones. (A) qRT-PCR analysis for Wnt target genes Axin2, Ctgf, and Lef1 using P21 rib bones.
Expression levels of Axin2, Ctgf, and Lef1 were increased significantly in cKO rib bones. Values in cKO bones (striped bar) are expressed relative to controls
(openbar).(B)qRT-PCRanalysisforDkk1,Lrp5,andSostusingP21ribbones.ExpressionlevelsofWntinhibitors(Dkk1andSost)werereducedsignificantlyin
cKO rib bones (striped bar), whereas expression of coreceptor Lrp5 was unchanged. (C) qRT-PCR analysis for Dkk1, Sost, and Bmpr1a using primary
osteoblasts from P10 Bmpr1a cKO and control calvariae. Expression levels of Dkk1, Sost, and Bmpr1a were reduced significantly in cKO osteoblasts (striped
bar) compared with control osteoblasts (open bar). (D) Suppressed expression of Dkk1 and Sost by Noggin treatment ex vivo, as assessed by qRT-PCR.
Newborn calvariae from wild-type mice were treated with Noggin (100ng/mL) for 5 days. The asterisk indicates a statistically significant difference
between Noggin treatment (Noggin
þ) and nontreatment (Noggin
–) from three independent experiments. (A–D) Mean SD; t test;
 p<.05;
  p<.02;
   p<.01.
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Fig. 7A). These results suggest that Dkk1 expression is regulated
by both Smad-mediated and p38 MAPK signaling, whereas Sost
expression is regulated mainly by Smad signaling (see Fig. 7B).
Discussion
We previously reported that loss of BMPRIA-mediated signaling
resulted in increased bone mass in embryos and adults
(14,15) and
discoveredthatsclerostin/SostisadownstreamtargetofBMPRIA
signaling during embryogenesis that inhibits Wnt to regulate
bone mass.
(14) In this study we found that Dkk1, another Wnt
inhibitor, is also a downstream target of BMPRIA signaling at the
weanling stage. Based on our findings, we propose a mechanism
by which Dkk1 is regulated by signaling through both Smad-
dependent and Smad-independent pathways in osteoblasts
during postnatal development, whereas Sost is regulated
predominantly by the Smad pathway (see Fig. 7).
There is a growing body of evidence to suggest that the BMP
and Wnt signaling pathways regulate one another synergistically
or antagonistically in a context and age-dependent manner.
(46–
49) The interplay of Wnt/b-catenin and BMP signaling pathways
has not been demonstrated previously during bone develop-
ment in vivo. However, we recently reported that BMP signaling
in osteoblasts downregulates canonical Wnt signaling during
embryonic bone development.
(14) Consistent with the effects
of BMP signaling during embryogenesis, we presently found
evidence for negative regulation of canonical Wnt signaling by
BMPRIA signaling in osteoblasts postnatally (see Fig. 2). Our
findings that embryonic and postnatal BMPRIA signaling
negatively regulate canonical Wnt signaling in osteoblasts agree
with other studies that have shown an inhibitory effect of BMP
signaling on Wnt signaling in lungs,
(50) intestines,
(49) hair,
(51) and
joints.
(48) Although many mouse models and human mutations
modifying the Wnt signaling pathway have been described, no
studies to date have addressed the in vivo interaction of BMP
and Wnt signaling in osteoblasts.
Recent studies using pluripotent mesenchymal cell lines have
suggested that BMP signaling may upregulate Wnt signaling
to synergistically regulate osteoblastogenesis,
(23,52) possibly
through an autocrine or paracrine loop.
(21) This is in contrast
with our mouse studies showing that BMP signaling down-
regulates Wnt signaling. The discrepancy may be due to the use
of mesenchymal cell lines rather than primary osteoblasts or the
supraphysiologic levels of in vitro BMP treatment or reflect the
coordinated action of multiple cell types including osteoclasts in
a physiologic setting compared with cell monoculture. The
potential importance of the physiologic context of these
pathways may be reflected in the finding that canonical Wnt
signaling was markedly upregulated in cKO mice (see Fig. 2B, C)
but only modestly increased in isolated Bmpr1a-deficient
osteoblasts (see Fig. 3A, B).
In mice, both Sost and Dkk1 expression levels were down-
regulated by disrupting Bmpr1a (see Fig. 4) and upregulated by
enhancing BMP signaling via caBmpr1a (see Fig. 6). These results,
which were replicated in cell culture (see Fig. 5A), suggest that
both Dkk1 and sclerostin/Sost are downstream targets of
BMPRIA. Previous reports support this notion because BMPRIA
ligands BMP2 and BMP4 induce Dkk1 expression during limb
development in mice and chickens,
(53,54) as well as Sost
expression in mouse and human osteoblasts.
(55,56) In parallel,
inhibition of BMP signaling with dorsomorphin suppressed the
expressionofDkk1andSost(seeFig.5B),resultinginupregulated
canonical Wnt signaling (see Fig. 3C). Noggin also inhibited Dkk1
and Sost expression (see Fig. 4D), consistent with previous
reports that Noggin inhibited Sost expression with upregulation
of Wnt signaling in mice
(14) and suppressed Dkk1 expression in
chickens.
(54) Although Dkk1 has been proposed to be a target of
BMP signaling in mouse limb development,
(53) this study
Fig. 5. Positive regulation of Dkk1 and Sost expression by BMP2. Primary
osteoblasts were isolated from wild-type newborn calvariae. (A) Dose-
dependent effects of BMP2 on Dkk1 and Sost expression as assessed by
qRT-PCR. mRNA was isolated from wild-type osteoblasts treated with
BMP2 at the indicated concentration for 3 hours. Values are expressed
relative to nontreated osteoblasts (mean SD; t test;
 p<.05;
  p<.01).
(B) Time course of Dkk1 and Sost expression levels using wild-type
osteoblasts treated with BMP2 (100ng/mL). (C) Effects of pretreatments
of primary osteoblasts with Smad-dependent inhibitor dorsomorphin.
mRNA was isolated from wild-type osteoblasts pretreated with dorso-
morphin(10mM) or DMSO in the absenceof serum for 1 hourprior to the
addition of BMP2 (100ng/mL) or PBS for 3 hours. Upregulation of Dkk1
and Sost expression by BMP2 treatment was restored by dorsomorphin
pretreatment, as assessed by qRT-PCR. Values are expressed relative
to osteoblasts without dorsomorphin and BMP2 (mean SD; t test;
 p<.05).
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regulates Dkk1 expression in osteoblasts. The finding that both
Smad-dependent and Smad-independent pathways appear to
contribute to Dkk1 expression, whereas Sost requires only Smad-
dependent signaling suggests differential regulation of these
genes by BMPRIA.
Both Dkk1 and sclerostin/Sost are expressed by osteoblasts as
secreted proteins that inhibit Wnt/b-catenin signaling by
binding to coreceptors low-density lipoprotein receptor–related
protein 5 and 6 (LRP5 and LRP6).
(36,37,57) Conventional knockouts
of Dkk1 die in utero from defective head induction and limb
formation.
(53) Mice heterozygous for Dkk1 (Dkk1
þ/  mice) exhibit
a high-bone-mass (HBM) phenotype,
(58) whereas overexpression
Fig. 6. Effects of Smad-dependent Bmpr1a signaling on Dkk1 and
Sost expression. (A) Positive regulation of Dkk1 and Sost expression by
overexpressing Smad-dependent Bmpr1a signaling. Primary osteoblasts
were isolated from constitutively active Bmpr1a (caBmpr1a) newborn
mice or littermate controls (Cre–,c a Bmpr1a
þ) and were treated with
4-hydroxyl tamoxifen (100ng/mL). Both Dkk1 expression and Sost
expression were increased significantly more than 5- and 10-fold, respec-
tively, in the caBmpr1a mutant osteoblasts (Cre
þ,c a Bmpr1a
þ) compared
with controls (Cre
–,c a Bmpr1a
þ), as assessed by qRT-PCR. Values of the
mutant osteoblasts (striped bar) are expressed relative to controls (open
bar) (mean SD; t test;
 
p < 0.01). (B) Radiodensity of rib bones and
sternum from rescued mice expressing caBmpr1a on a Bmpr1a cKO
background (Cre
þ,c a Bmpr1a
þ, Bmpr1a
fx/fx), littermate Bmpr1a cKO mice
(Cre
þ,c a Bmpr1a
–, Bmpr1a
fx/fx) and littermate controls (Cre
–,c a Bmpr1a
þ,
or Bmpr1a
fx/fx)a tP 21 when assessed by X-ray imaging. White arrows
indicate rib flaring observed in cKO and rescued mice. (C) BMD as
determined by DXA using ribs from control (open bar), cKO (striped
bar), and rescued mice (gray bar)a tP 21. BMD of rescued sternums was
reduced significantly by 10% compared with cKO sternum and increased
by 6% compared with controls. Values are expressed as mean SD
(n>6; t test,
 p¼.07,
  p<.05).
Fig. 7. Effects of non-Smad signaling on Dkk1 and Sost expression in
osteoblasts. (A) Effects of p38 MAPK inhibitor SB202190 on Dkk1 and Sost
expression using primary osteoblasts from newborn wild-type mice as
assessed by qRT-PCR. mRNA was isolated from wild-type osteoblasts
pretreated with SB202190 (10mM) or DMSO in the absence of serum for
1 hour prior to the addition of BMP2 (100ng/mL) or PBS for 3 hours.
Upregulation of Dkk1 expression by BMP2 treatment was restored by
SB202190 pretreatment. Sost expression was increased significantly by
BMP2 treatment with SB202190 pretreatment. Values are expressed
relative to untreated osteoblasts (neither SB202190 nor BMP2)
(mean SD; t test;
 p<.05;
  p<.01). (B) A proposed model of the
relationship between BMPRIA and canonical Wnt signaling through
Dkk1 and sclerostin/Sost in bone. BMPRIA signaling upregulates Sost
expression primarily through Smad-dependent signaling while upregu-
lating Dkk1 expression through both Smad and non-Smad signaling
(p38 MAPK). Both Dkk1 and sclerostin/Sost inhibit canonical Wnt signal-
ing, leading to a decrease in bone mass. Dkk1 and sclerostin/Sost play
an important role in regulating bone mass as downstream effectors of
BMPRIA signaling.
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(59) In addition,
increased DKK1 expression in bone marrow also has been
associated with lytic bone lesions in patients with multiple
myeloma.
(60) Collectively, these results support the hypothesis
that Dkk1 functions as a potent negative regulator of bone mass.
Sost KO mice are viable and exhibit increased bone mass,
(61)
similar to Dkk1
þ/  mice. In humans, loss-of-function and
hypomorphic mutations in SOST cause sclerosteosis
(62,63) and
Van Buchem disease,
(64,65) respectively, with an HBM phenotype.
Consistent with these observations, Bmpr1a cKO mice, which are
deficient in Dkk1 and Sost expression, show an HBM phenotype.
Furthermore, increased expression of Dkk1 and Sost in
osteoblasts by constitutively activated BMPRIA signaling is
associated with partial rescue of the Bmpr1a cKO bone
phenotype. Our present data support the interpretation that
Dkk1 and sclerostin/Sost act physiologically as inhibitors of
canonical Wnt signaling and therefore as negative regulators of
bone mass in mice.
Both Smad-dependent and Smad-independent pathways are
important for BMP signaling. p38 MAPK plays a central role in
Smad-independent pathways of TGF-b/BMP signaling
(41–45) by
accelerating osteoblastogenesis,
(66,67) which canbe repressed by
p38 MAPK inhibitors.
(68,69) This study demonstrated that the p38
MAPKinhibitor SB202190 prevented the upregulation of Dkk1 by
BMP2 but did not alter Sost expression in osteoblasts (see
Fig. 7A). This is consistent with a previous report showing that
upregulation of Dkk by BMP5 was severely impaired after
cotreatment with p38 MAPK inhibitors in chick limb buds.
(42) The
p38MAPKpathwaythusappearstocontributeatleastpartofthe
regulation of Wnt signaling by BMPRIA. Given the demonstrated
importance of p38 MAPK signaling in osteoblastogenesis, it is
highly plausible that additional Smad-independent mechanisms
may link BMP signaling and Wnt signaling in this lineage.
The Food and Drug Administration (FDA) has approved BMP2
and BMP7 for clinical use in long bone open fractures, nonunion
fractures, and spinal fusion. However, despite significant
evidence of their potential for bone regeneration in animal
and preclinical studies, the current clinical data supporting the
effectiveness of BMP therapy is somewhat unconvincing.
(70,71)
The lack of a clear benefit from BMPs might stem from an
incomplete understanding of the variable and context-sensitive
effects BMPs exert on diverse cell types in bone, including
chondrocytes, osteoblasts, and osteoclasts. Studies focusing on
BMP receptors in chondrocytes including mesenchymal cells
suggest that these cells respond to BMP signaling by increasing
bone mass during the endochondral formation process.
(72–75) In
contrast, when we examined function of BMPRIA in osteoblasts
with respect to bone mass determination, BMP signals
consistently inhibited canonical Wnt signaling and bone mass
while exerting concordant effects on Dkk1 and Sost. Our current
evidence adds an important nuance to the conventional notion
of BMPs as inducers of osteogenesis and positive regulators of
bone mass owing to their inverse effects on Wnt signaling in
osteoblasts. The functions of BMPRIA signaling in osteoclasts
remain largely unknown and merit future study, although we
previously observed a significant decrease in osteoblast-
dependent osteoclastogenesis in cKO mice.
(14,15) This revision
of our understanding of the BMP signaling pathway in clinical
therapeutics might suggest that in some circumstances BMP
inhibition would be desirable for promoting bone mass.
Understanding the complex roles of the BMP signaling pathway
in chondrocytes, osteoblasts, osteoclasts, and other cell types
that contribute to bone development, homeostasis, and
remodeling not only will help to improve our knowledge of
the dynamic processes that are perturbed in settings of bone
fracture, ovariectomy, orchiectomy, mechanical loading, and
aging but also may provide novel therapeutically useful
strategies.
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